NEW YORK, Jan. 25, 2011 /PRNewswire/ — Reportlinker.com
announces that a new market research report is available in its
catalogue:
Brand Erosion Post-Patent Expiry – An analysis of small
molecule brand erosion post-patent expiry
http://www.reportlinker.com/p0364060/Brand-Erosion-Post-Patent-Expiry-–-An-analysis-of-small-molecule-brand-erosion-post-patent-expiry.html
IntroductionPharma is facing slowing sales growth in the
developed pharmaceutical markets, driven by increasing generic
competition. However, the speed and severity of brand erosion is by
no means equal across countries, prescribing setting, therapy area
and formulation type; factors which are of key importance when
managing and forecasting branded drug sales.
Features and benefits* Analyzes brand erosion (in terms of
volume and value) in the US, Japan, France, Germany, Italy, Spain,
UK, Australia China and Russia* Assesses brand erosion across the
two major prescribing settings (retail and hospital)* Examines
brand erosion across the various different therapy areas* Analyzes
brand erosion according to drug formulation (oral, oral long
lasting, parenteral and other formulation types)
HighlightsBrands tended not to experience generic erosion in
China following patent expiry since they often face generic
competition from the outset, and instead continue to grow both in
terms of volume and value. Brand erosion was greater in terms of
speed and severity in the hospital setting most likely reflecting
the greater brand loyalty among patients in the retail setting. In
ter
‘/>”/>
SOURCE